Suppr超能文献

胺碘酮相关性甲状腺毒症的外科治疗:梅奥诊所经验

Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience.

作者信息

Houghton Scott G, Farley David R, Brennan Michael D, van Heerden Jon A, Thompson Geoffrey B, Grant Clive S

机构信息

Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

出版信息

World J Surg. 2004 Nov;28(11):1083-7. doi: 10.1007/s00268-004-7599-6.

Abstract

Amiodarone-associated thyrotoxicosis (AAT) is often poorly tolerated owing to underlying cardiac disease, and it is frequently refractory to conventional medical treatment. The goal of this study was to describe the patient characteristics, management, and outcomes of all the patients treated surgically for AAT at a single institution. We conducted a retrospective chart review of all patients managed surgically for AAT (April 1985 through November 2002) at the Mayo Clinic in Rochester, Minnesota. Altogether, 29 men and 5 women, ages 39 to 85 years (median 60 years), treated with amiodarone for 3 to 108 months underwent near-total or total thyroidectomy. Frequent symptoms were worsening heart failure, fatigue, weight loss, and tremor. Altogether, 12 patients failed medical management of their AAT, and 21 received no preoperative medical therapy. One patient had been successfully managed medically but required definitive treatment. Common indications for operation were the need to remain on amiodarone, cardiac decompensation, medically refractory disease, and severe symptoms, both hyperthyroid and cardiac, necessitating prompt resolution. The median+/-SD American Society of Anesthesiologists (ASA) classification (1 = healthy through 5 = moribund) was 3.00+/-0.58. A total of 27 specimens had histology consistent with AAT. Complications included death (n = 3), rehospitalization (n = 3), symptomatic hypocalcemia (n = 2), pneumonia (n = 2), cervical hematoma (n = 1), prolonged ventilatorywean (n = 1), and stroke (n = 1); one patient developed hypotension, adult respiratory distress syndrome, and sepsis. Of the 31 surviving patients, 25 (80%) remained on amiodarone postoperatively. The median follow-up was 29 months, at which time all surviving patients were free of hyperthyroid symptoms. Thyroidectomy is an effective treatment for AAT but has a high incidence of perioperative morbidity and mortality. The cardiovascular co-morbidities and high operative risk in this group of patients may account for the increased complication rate.

摘要

胺碘酮相关性甲状腺毒症(AAT)常因潜在的心脏疾病而耐受性差,且对传统药物治疗往往无效。本研究的目的是描述在单一机构接受手术治疗的所有AAT患者的特征、治疗方法及结局。我们对明尼苏达州罗切斯特市梅奥诊所1985年4月至2002年11月期间接受手术治疗的所有AAT患者进行了回顾性病历审查。共有29名男性和5名女性,年龄39至85岁(中位年龄60岁),服用胺碘酮3至108个月,接受了近全甲状腺切除术或全甲状腺切除术。常见症状为心力衰竭加重、疲劳、体重减轻和震颤。共有12例患者的AAT药物治疗失败,21例患者术前未接受药物治疗。1例患者药物治疗曾成功,但需要确定性治疗。手术的常见指征包括需要继续使用胺碘酮、心脏失代偿、药物难治性疾病以及严重症状,包括甲状腺功能亢进和心脏症状,需要迅速缓解。美国麻醉医师协会(ASA)分类(1 = 健康至5 = 濒死)的中位数±标准差为3.00±0.58。共有27份标本的组织学与AAT一致。并发症包括死亡(n = 3)、再次住院(n = 3)、有症状的低钙血症(n = 2)、肺炎(n = 2)、颈部血肿(n = 1)、通气脱机时间延长(n = 1)和中风(n = 1);1例患者出现低血压、成人呼吸窘迫综合征和脓毒症。在31名存活患者中,25名(80%)术后继续使用胺碘酮。中位随访时间为29个月,此时所有存活患者均无甲状腺功能亢进症状。甲状腺切除术是治疗AAT的有效方法,但围手术期发病率和死亡率较高。这组患者的心血管合并症和高手术风险可能是并发症发生率增加的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验